S&P 500   3,089.10 (-0.16%)
DOW   27,731.83 (-0.19%)
QQQ   200.71 (-0.44%)
CGC   15.64 (-15.46%)
BABA   183.17 (+0.38%)
GE   11.33 (+0.35%)
F   8.81 (+0.00%)
ACB   3.22 (-9.31%)
BAC   32.61 (-0.58%)
DIS   147.75 (-0.65%)
S&P 500   3,089.10 (-0.16%)
DOW   27,731.83 (-0.19%)
QQQ   200.71 (-0.44%)
CGC   15.64 (-15.46%)
BABA   183.17 (+0.38%)
GE   11.33 (+0.35%)
F   8.81 (+0.00%)
ACB   3.22 (-9.31%)
BAC   32.61 (-0.58%)
DIS   147.75 (-0.65%)
S&P 500   3,089.10 (-0.16%)
DOW   27,731.83 (-0.19%)
QQQ   200.71 (-0.44%)
CGC   15.64 (-15.46%)
BABA   183.17 (+0.38%)
GE   11.33 (+0.35%)
F   8.81 (+0.00%)
ACB   3.22 (-9.31%)
BAC   32.61 (-0.58%)
DIS   147.75 (-0.65%)
S&P 500   3,089.10 (-0.16%)
DOW   27,731.83 (-0.19%)
QQQ   200.71 (-0.44%)
CGC   15.64 (-15.46%)
BABA   183.17 (+0.38%)
GE   11.33 (+0.35%)
F   8.81 (+0.00%)
ACB   3.22 (-9.31%)
BAC   32.61 (-0.58%)
DIS   147.75 (-0.65%)
Log in

Axsome Therapeutics Stock Price, Forecast & Analysis (NASDAQ:AXSM)

$26.22
+0.52 (+2.02 %)
(As of 11/14/2019 11:37 AM ET)
Today's Range
$25.29
Now: $26.22
$26.22
50-Day Range
$14.86
MA: $21.95
$26.69
52-Week Range
$1.94
Now: $26.22
$30.50
Volume6,293 shs
Average Volume839,285 shs
Market Capitalization$904.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.61
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.20 per share

Profitability

Net Income$-30,970,000.00

Miscellaneous

Employees29
Market Cap$904.85 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.


Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics Inc (NASDAQ:AXSM) announced its earnings results on Thursday, November, 7th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.15. View Axsome Therapeutics' Earnings History.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Axsome Therapeutics.

What price target have analysts set for AXSM?

9 brokerages have issued 12-month price targets for Axsome Therapeutics' stock. Their forecasts range from $25.00 to $48.00. On average, they expect Axsome Therapeutics' share price to reach $35.13 in the next year. This suggests a possible upside of 35.6% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.

What is the consensus analysts' recommendation for Axsome Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.

Has Axsome Therapeutics been receiving favorable news coverage?

News headlines about AXSM stock have been trending somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Axsome Therapeutics earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Axsome Therapeutics.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 6,110,000 shares, an increase of 9.3% from the September 15th total of 5,590,000 shares. Based on an average daily volume of 872,000 shares, the short-interest ratio is presently 7.0 days. Approximately 23.3% of the company's shares are short sold. View Axsome Therapeutics' Current Options Chain.

Who are some of Axsome Therapeutics' key competitors?

What other stocks do shareholders of Axsome Therapeutics own?

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:
  • Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)
  • Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)
  • Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)
  • Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)
  • Joseph Debrah-Afful, Director of Fin.

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rhumbline Advisers (0.09%), Janney Montgomery Scott LLC (0.08%), California Public Employees Retirement System (0.08%), Virginia Retirement Systems ET AL (0.05%), Tower Research Capital LLC TRC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics.

Which institutional investors are selling Axsome Therapeutics stock?

AXSM stock was sold by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC and Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Axsome Therapeutics.

Which institutional investors are buying Axsome Therapeutics stock?

AXSM stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Virginia Retirement Systems ET AL, Janney Montgomery Scott LLC and Rhumbline Advisers. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad and Nick Pizzie. View Insider Buying and Selling for Axsome Therapeutics.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $25.90.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $893.81 million. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.View Additional Information About Axsome Therapeutics.

What is Axsome Therapeutics' official website?

The official website for Axsome Therapeutics is http://axsome.com/.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.


MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  509
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Featured Article: What are no-load funds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel